As of 2024-12-14, the EV/EBITDA ratio of Profound Medical Corp (PRN.TO) is -7.39. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. PRN.TO's latest enterprise value is 234.30 mil CAD. PRN.TO's TTM EBITDA according to its financial statements is -31.73 mil CAD. Dividing these 2 quantities gives us the above PRN.TO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 20.6x - 23.6x | 22.0x |
| Forward P/E multiples | 19.5x - 22.9x | 21.9x |
| Fair Price | (36.32) - (40.58) | (38.78) |
| Upside | -439.4% - -479.3% | -462.4% |
| Date | EV/EBITDA |
| 2024-12-10 | -5.26 |
| 2024-12-09 | -5.27 |
| 2024-12-06 | -5.16 |
| 2024-12-05 | -5.48 |
| 2024-12-04 | -5.65 |
| 2024-12-03 | -5.74 |
| 2024-12-02 | -5.73 |
| 2024-11-29 | -5.59 |
| 2024-11-28 | -5.28 |
| 2024-11-27 | -5.48 |
| 2024-11-26 | -5.27 |
| 2024-11-25 | -5.12 |
| 2024-11-22 | -5.14 |
| 2024-11-21 | -5.10 |
| 2024-11-20 | -5.18 |
| 2024-11-19 | -5.27 |
| 2024-11-18 | -5.39 |
| 2024-11-15 | -5.36 |
| 2024-11-14 | -5.51 |
| 2024-11-13 | -5.48 |
| 2024-11-12 | -5.52 |
| 2024-11-11 | -5.58 |
| 2024-11-08 | -5.88 |
| 2024-11-07 | -6.09 |
| 2024-11-06 | -5.46 |
| 2024-11-05 | -5.32 |
| 2024-11-04 | -5.54 |
| 2024-11-01 | -4.97 |
| 2024-10-31 | -4.88 |
| 2024-10-30 | -5.02 |
| 2024-10-29 | -4.96 |
| 2024-10-28 | -5.04 |
| 2024-10-25 | -4.85 |
| 2024-10-24 | -4.79 |
| 2024-10-23 | -4.81 |
| 2024-10-22 | -4.97 |
| 2024-10-21 | -4.98 |
| 2024-10-18 | -5.21 |
| 2024-10-17 | -5.18 |
| 2024-10-16 | -5.10 |
| 2024-10-15 | -5.10 |
| 2024-10-11 | -5.05 |
| 2024-10-10 | -4.96 |
| 2024-10-09 | -5.02 |
| 2024-10-08 | -5.09 |
| 2024-10-07 | -5.00 |
| 2024-10-04 | -5.17 |
| 2024-10-03 | -5.22 |
| 2024-10-02 | -5.36 |
| 2024-10-01 | -5.21 |